Effects of BLa80 and LRa05 on the Gut Microbiota Metabolite Profile of Healthy Individuals

Condition(s) studied

Investigational drug(s) / intervention(s)

Placebo: The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).

BLa80: The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).

LRa05: The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).

Study summary

Gut microbiota play a key role in polyphenol metabolism, participating in the breakdown of dietary components and producing various small molecule metabolites that affect human health. However, little is currently known about how gut microbes metabolize dietary compounds and produce bioactive metabolites. This study aims to use metabolomics to precisely identify food-derived metabolites in the blood to investigate whether probiotics (BLa80, LRa05) can enhance the breakdown of dietary components and improve their absorption and utilization in the human body.

Eligibility

Primary outcome measure(s)

• Serum metabolomic profiles measured by HPLC-MS/MS — Baseline (week 0), week 4, and week 8 post intervention
  Untargeted serum metabolomic profiling will be performed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) to assess changes in circulating metabolite concentrations over time.

Trial sites (1)

More Wecare Probiotics Co., Ltd. trials in China